Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))

Muhammad Ali, Jennifer Mooi, Nathan Lawrentschuk, Rana R. McKay, Raquibul Hannan, Simon S. Lo, William A. Hall, Shankar Siva

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that Section 3.9, paragraph, In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break, and efficacy was defined as 1-yr PFS of 70%. Patients received SABR for all lesions and were maintained off systemic therapy. While the efficacy objective was not met, at a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events should read as follows: “In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break. Patients received SABR for all lesions and were maintained off systemic therapy. At a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events” Table 1 row (Correa et al.) column (Dose (Gy)/fraction) should read 26/1, 30–40/3–5. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
JournalEuropean urology
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))'. Together they form a unique fingerprint.

Cite this